Prucalopride

For the treatment of Chronic Idiopathic Constipation (CIC) in adults, the standard recommended dose of Prucalopride is 2 mg taken orally once daily. Clinical studies have shown that doses higher than 2 mg do not provide additional efficacy and may increase the risk of side effects. Healthcare providers typically assess the effectiveness of the medication after 4 weeks of continuous use. If the patient has not experienced a significant improvement in bowel movement frequency by that time, the physician may re-evaluate the treatment plan.

As of 2026, the safety and effectiveness of Prucalopride in pediatric patients (children under the age of 18) have not been established. Clinical trials in children have been conducted, but the drug is not currently FDA-approved for this population. Parents should never give Prucalopride to a child unless specifically directed by a pediatric specialist in a clinical trial or highly specialized setting.

Renal Impairment

Because Prucalopride is primarily excreted by the kidneys, dosage adjustments are necessary for patients with decreased kidney function.

• Mild to Moderate Renal Impairment: No dose adjustment is typically required for patients with a Creatinine Clearance (CrCl) of 30 mL/min or higher.
• Severe Renal Impairment: For patients with a CrCl less than 30 mL/min, the recommended dose is 1 mg once daily.
• End-Stage Renal Disease (ESRD): Prucalopride is generally not recommended for patients requiring dialysis due to a lack of clinical data in this specific population.

Hepatic Impairment

• Mild to Moderate Hepatic Impairment (Child-Pugh A or B): No dose adjustment is required.
• Severe Hepatic Impairment (Child-Pugh C): While not strictly contraindicated, healthcare providers may choose to start with a 1 mg dose and monitor the patient closely, as data in severe liver disease is limited.

Elderly Patients

For patients aged 65 and older, the starting dose is often 1 mg once daily. If this dose is well-tolerated but does not produce the desired effect, the healthcare provider may increase the dose to 2 mg once daily. This cautious approach accounts for the potential for age-related declines in kidney function.

Prucalopride should be taken exactly as prescribed by your doctor.

• Timing: The medication can be taken at any time of day, but many patients find it most effective to take it at the same time each morning to establish a routine.
• Food: Prucalopride may be taken with or without food. Its absorption is not affected by meal content.
• Administration: The tablet should be swallowed whole with a glass of water. Do not crush or chew the tablet unless your pharmacist or doctor specifically tells you to do so.
• Storage: Keep the medication in its original blister pack or bottle to protect it from moisture. Store at room temperature (68°F to 77°F or 20°C to 25°C).

If you miss a dose of Prucalopride, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects like severe headache or diarrhea.

In the event of an overdose, patients may experience an intensification of known side effects, particularly severe headache, nausea, and diarrhea. If you suspect an overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment for overdose is generally supportive, focusing on hydration and managing symptoms. Because Prucalopride is highly selective, cardiovascular toxicity is unlikely, but medical monitoring is still essential.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop taking Prucalopride without medical guidance, as your symptoms may return.

Side effects from Prucalopride are most common during the first few days of treatment and often subside as the body adjusts to the medication. The most frequently reported side effects include:

• Headache: This is the most common side effect, occurring in approximately 15-20% of patients. It typically happens on the first day of treatment and usually resolves within 24 to 48 hours without the need to stop the medication.
• Nausea: Feeling sick to the stomach is common initially. Taking the medication with food may help mitigate this sensation.
• Abdominal Pain or Cramping: As the medication begins to stimulate the muscles of the colon, some patients may feel cramping or 'gas-like' pains.
• Diarrhea: Because the drug speeds up intestinal transit, some patients may experience loose or frequent stools. If diarrhea becomes severe or leads to dehydration, contact your doctor.

• Dizziness: Some patients report a feeling of lightheadedness or vertigo.
• Vomiting: Less common than nausea, but may occur in sensitive individuals.
• Dyspepsia (Indigestion): A feeling of fullness or burning in the upper abdomen.
• Flatulence: Increased gas production as the gut motility changes.
• Fatigue: A general feeling of tiredness or low energy.

• Palpitations: A sensation of the heart racing or skipping a beat. While Prucalopride is selective and generally heart-safe, any heart rhythm changes should be reported.
• Pollakiuria: An increased frequency of urination.
• Rectal Bleeding: This is rare and may be related to the passing of hard stools or underlying hemorrhoids being irritated by increased bowel movements.

While Prucalopride is generally well-tolerated, certain symptoms require immediate medical intervention.

> Warning: Stop taking Prucalopride and call your doctor immediately if you experience any of the following:

• Suicidal Ideation and Behavior: In clinical trials, a small number of patients reported new or worsening depression, suicidal thoughts, or changes in mood. This is a rare but serious psychiatric side effect.
• Severe Abdominal Pain: While mild cramping is normal, intense or worsening pain could indicate a more serious condition like intestinal perforation or obstruction.
• Signs of an Allergic Reaction: This includes hives, swelling of the face, lips, tongue, or throat, and difficulty breathing (anaphylaxis).
• Severe Persistent Diarrhea: If you cannot keep fluids down or feel extremely weak and dizzy, you may be experiencing severe dehydration or electrolyte imbalance.

Data on the long-term use of Prucalopride (over 12-18 months) suggests that the drug maintains its efficacy and safety profile. There is no evidence that Prucalopride causes 'lazy bowel syndrome' or dependency in the way that some stimulant laxatives (like senna or bisacodyl) might. However, patients should be monitored periodically to ensure the drug is still necessary and effective for their condition.

As of 2026, there are no FDA black box warnings for Prucalopride. However, the FDA does require a specific warning in the 'Warnings and Precautions' section regarding suicidal ideation and behavior. This was added based on a small number of cases observed during clinical development, and patients are advised to monitor their mood closely.

Report any unusual symptoms or changes in your mental health to your healthcare provider immediately. It is helpful to keep a 'symptom diary' during the first two weeks of treatment to track how your body responds to the medication.

Prucalopride is a potent prokinetic agent and should only be used by individuals for whom it has been specifically prescribed. It is not a 'rescue' laxative for occasional constipation but a maintenance therapy for chronic conditions. Patients should be aware that while the drug is highly selective, it affects the entire gastrointestinal tract and can interact with various physiological systems.

No FDA black box warnings for Prucalopride. The medication has been determined to have a favorable safety profile when used according to the approved labeling. Unlike previous drugs in this class, Prucalopride does not carry a black box warning for cardiovascular events.

Allergic Reactions / Anaphylaxis Risk

Patients with a known hypersensitivity to Prucalopride succinate or any of the inactive ingredients (such as lactose) should not take this medication. Signs of a serious reaction include skin rash, itching, and swelling of the extremities or face.

Intestinal Perforation and Obstruction

Prucalopride should not be used if there is a known or suspected mechanical obstruction of the bowel or if the patient has a condition that increases the risk of intestinal perforation (a hole in the wall of the gut). Conditions like Crohn's disease, ulcerative colitis, or toxic megacolon are high-risk factors.

Suicidality Warnings

Healthcare providers and patients should be alert to the emergence of suicidal thoughts and behaviors, new or worsening depression, or other unusual changes in mood or behavior. If these symptoms occur, the medication should be discontinued immediately, and the patient should seek psychiatric evaluation. This warning applies to patients with and without a history of psychiatric disorders.

Cardiovascular Safety

While Prucalopride is highly selective for the 5-HT4 receptor and does not typically affect the QT interval (a measure of heart rhythm), patients with a history of severe arrhythmias or significant heart disease should still use the drug with caution and under close medical supervision.

Routine laboratory monitoring (such as frequent blood draws) is generally not required for healthy adults taking Prucalopride. However, specific populations may need:

• Renal Function Tests: Baseline and periodic Creatinine Clearance (CrCl) tests for elderly patients or those with known kidney disease to ensure the dosage remains appropriate.
• Mental Health Screening: Doctors may ask patients to complete mood questionnaires before and during treatment to monitor for psychiatric changes.

Prucalopride has been associated with dizziness and fatigue in some patients, particularly during the first few days of treatment. Use caution when driving or operating heavy machinery until you know how the medication affects you.

There is no known direct chemical interaction between Prucalopride and alcohol. However, alcohol can irritate the gastrointestinal tract and may worsen side effects like dizziness or nausea. It is generally advisable to limit alcohol consumption while managing chronic constipation.

Prucalopride does not typically require a tapering schedule (gradually reducing the dose). It can usually be stopped abruptly without withdrawal symptoms. However, stopping the medication will likely result in the return of constipation symptoms. Always discuss your plan to stop the medication with your doctor first.

> Important: Discuss all your medical conditions, including any history of depression or kidney disease, with your healthcare provider before starting Prucalopride.

There are no medications that are strictly contraindicated (absolutely forbidden) for use with Prucalopride based on chemical incompatibility. However, Prucalopride should never be used in patients with intestinal perforation or severe inflammatory bowel diseases. Using Prucalopride in the presence of a mechanical bowel obstruction can lead to severe complications, including bowel rupture.

• Anticholinergic Agents: Drugs such as benztropine, oxybutynin, or certain older antidepressants have 'anticholinergic' effects, which slow down the gut. Since Prucalopride works by stimulating the gut (cholinergic-like effect), these medications can counteract each other, reducing the effectiveness of Prucalopride.
• Other Prokinetics: Taking Prucalopride with other drugs that stimulate gut motility (like metoclopramide) may increase the risk of severe abdominal cramping and diarrhea.

• Ketoconazole and Erythromycin: These drugs are potent inhibitors of certain metabolic pathways. While Prucalopride is not heavily metabolized by the liver, studies have shown that ketoconazole can increase the systemic exposure (amount in the blood) of Prucalopride by about 40%. While this usually doesn't require a dose change, patients should be monitored for increased side effects.
• Oral Contraceptives: In some cases, severe diarrhea caused by Prucalopride could potentially reduce the absorption and effectiveness of oral birth control pills. Women using hormonal contraceptives should consider using an additional barrier method (like condoms) if they experience significant diarrhea while taking Prucalopride.

• General Food Intake: Prucalopride can be taken with or without food. High-fat meals do not significantly alter the absorption of the drug.
• Grapefruit Juice: Unlike many other medications, Prucalopride does not have a major interaction with grapefruit juice, as it is not a primary substrate for the CYP3A4 enzyme.

• St. John's Wort: This herbal supplement can induce enzymes that might slightly lower the levels of Prucalopride in the blood, potentially reducing its efficacy.
• Fiber Supplements: While often used for constipation, excessive fiber intake combined with Prucalopride may cause increased bloating and gas in some individuals. It is best to coordinate fiber use with your doctor's advice.

Prucalopride is not known to interfere with common laboratory tests, such as blood glucose, liver enzymes, or urine drug screens. However, always inform the laboratory staff and your doctor that you are taking this medication before any diagnostic testing.

For each major interaction, the mechanism is usually either pharmacodynamic (the drugs have opposing or additive effects on the body) or pharmacokinetic (one drug changes how the other is absorbed or excreted). The clinical consequence is typically either reduced effectiveness of the constipation treatment or an increase in GI-related side effects. The management strategy usually involves adjusting the timing of doses or choosing alternative medications for non-constipation issues.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter laxatives and vitamins.

There are specific medical scenarios where Prucalopride must NEVER be used because the risks far outweigh any potential benefits.

• Hypersensitivity: Anyone with a documented allergy to Prucalopride or any of its tablet components (e.g., microcrystalline cellulose, lactose monohydrate, magnesium stearate). An allergic reaction can lead to life-threatening anaphylaxis.
• Intestinal Perforation or Obstruction: If a patient has a physical blockage in the bowel (mechanical obstruction) or a hole in the intestinal wall (perforation), stimulating gut motility with Prucalopride could cause catastrophic injury or death.
• Severe Inflammatory Bowel Disease: This includes active Crohn’s disease, Ulcerative Colitis, and Toxic Megacolon. These conditions involve significant inflammation and weakening of the intestinal walls; Prucalopride's stimulatory effect could exacerbate the inflammation or lead to perforation.
• Severe Renal Failure Requiring Dialysis: Due to the lack of clinical safety data and the drug's primary reliance on renal clearance, it is contraindicated in this specific population.

These are conditions where the doctor must carefully weigh the risks and benefits before prescribing Prucalopride:

• History of Arrhythmia: While Prucalopride is selective, patients with 'Long QT Syndrome' or those taking other QT-prolonging drugs should be monitored closely.
• History of Depression or Suicidal Ideation: Because of the reported psychiatric side effects, patients with a history of mental health struggles require more frequent check-ins.
• Pregnancy and Lactation: Use is generally avoided unless the benefit clearly justifies the potential risk to the fetus or infant.

There is no known cross-sensitivity between Prucalopride and other classes of laxatives (like osmotic or stimulant laxatives). However, if a patient has had a severe reaction to other serotonin-related drugs (like 5-HT3 antagonists used for nausea, such as ondansetron), the physician may exercise additional caution, although the receptor targets are different.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of abdominal surgery or inflammatory conditions, before prescribing Prucalopride.

As of 2026, Prucalopride is generally not recommended during pregnancy. It is classified by many regulatory bodies in a category suggesting that while animal studies may not show direct fetal harm, there is 'limited data' in human pregnancies.

• First Trimester: This is the critical period for organ development. Data is insufficient to rule out a risk of major birth defects or miscarriage.
• Pregnancy Registry: Patients who become pregnant while taking Prucalopride are often encouraged to enroll in a pregnancy surveillance registry to help collect more data for future safety profiles.
• Clinical Decision: Use during pregnancy should only be considered if the mother's need for the drug is absolute and other safer alternatives have failed.

Prucalopride is excreted in human breast milk. While the amount a nursing infant would ingest is relatively low, the long-term effects of exposure to a prokinetic agent on a developing infant's gastrointestinal and nervous systems are unknown.

• Recommendation: Healthcare providers usually suggest either discontinuing the drug or discontinuing breastfeeding, taking into account the importance of the drug to the mother.

Prucalopride is not approved for use in children under the age of 18. Clinical trials have not sufficiently demonstrated that the drug is effective or safe for the developing gastrointestinal tracts of pediatric patients. Growth and developmental effects have not been long-term studied in this population.

In clinical trials, approximately 15% of participants were 65 years of age or older.

• Pharmacokinetics: Older adults may have reduced renal clearance, leading to higher levels of the drug in the blood.
• Dosing: A lower starting dose of 1 mg is typically recommended for patients over 65.
• Risks: Elderly patients may be more susceptible to dizziness, which increases the risk of falls. Close monitoring of hydration status is also important if diarrhea occurs.

The kidneys are the primary route for Prucalopride elimination.

• Mild-to-Moderate (CrCl > 30 mL/min): No dose adjustment needed.
• Severe (CrCl < 30 mL/min): The dose must be reduced to 1 mg once daily to prevent drug accumulation and toxicity.
• Dialysis: Not recommended as the drug's behavior during dialysis has not been adequately characterized.

• Mild-to-Moderate: No adjustment needed.
• Severe (Child-Pugh C): Use with caution. While the liver is not the primary site of clearance, severe liver disease can affect overall drug metabolism and fluid balance, necessitating a lower starting dose (1 mg) and careful clinical observation.

> Important: Special populations require individualized medical assessment and should never start Prucalopride without a detailed consultation with a specialist.

Prucalopride is a selective, high-affinity 5-HT4 (serotonin-4) receptor agonist. Serotonin receptors are found throughout the body, but the 5-HT4 subtype is specifically involved in the regulation of gastrointestinal motility.

When Prucalopride binds to these receptors on the enteric neurons within the myenteric plexus (the 'brain of the gut'), it stimulates the release of excitatory neurotransmitters, primarily acetylcholine. This release triggers a coordinated contraction of the smooth muscle in the colon. Most importantly, Prucalopride induces High-Amplitude Propagating Contractions (HAPCs). These are the specific types of bowel movements that move large amounts of waste through the colon toward the rectum. Unlike osmotic laxatives that just pull water into the stool, Prucalopride restores the natural 'pumping' action of the bowel.

• Dose-Response: There is a clear dose-response relationship up to 2 mg. Beyond 2 mg, the 'ceiling effect' is reached where no further benefit is seen, but side effects increase.
• Time to Onset: Most patients experience their first bowel movement within 2 to 3 days of starting regular treatment, though some may respond within hours of the first dose.
• Selectivity: Prucalopride is >150-fold more selective for 5-HT4 receptors than for other serotonin receptors (like 5-HT1 or 5-HT2) or the hERG potassium channel, which explains its superior safety profile compared to older drugs like cisapride.

| Parameter | Value |

|---|---|

| Bioavailability | >90% |

| Protein Binding | ~30% (primarily to albumin) |

| Half-life | 24 - 30 hours |

| Tmax | 2 - 3 hours |

| Metabolism | Minimal (Minor CYP3A4 involvement) |

| Excretion | Renal (~60% unchanged), Fecal (~4%) |

• Molecular Formula: C18H26ClN3O3 (as Prucalopride)
• Molecular Weight: 367.87 g/mol (free base); 485.96 g/mol (as succinate salt)
• Solubility: Soluble in water and methanol.
• Structure: It is a benzofurancarboxamide derivative. The succinate salt form is used in commercial tablets to ensure stability and consistent absorption.

Prucalopride is classified as a Gastrointestinal Prokinetic Agent and a Serotonin-4 Receptor Agonist. It is the first drug in this class to be approved for CIC in the United States that does not have the severe cardiovascular restrictions associated with its predecessors. It is often grouped with other motility agents like linaclotide or plecanatide, though those drugs work via different mechanisms (guanylate cyclase-C agonists).